NCNA - Rasio rega marang prakiraan pendapatan NuCana PLC

NuCana (NCNA) - logo korporat

This P/S metric chart from the GURU.Markets terminal shows that is the current indicator for NuCana plc (NCNA). This price action reflects the outsourcing of production in the US and UK to reduce infrastructure costs. NuCana plc (NCNA) management is implementing the ProTide platform to overcome tumor resistance to therapy, while the company maintains environmental standards for biohazardous waste disposal during clinical trials.

NuCana Corp - Prakiraan rega marang pendapatan NCNA (periode 04.07.2022 - 16.11.2026)

Rincian metrik komprehensif lan analitis NuCana Corp (NCNA)

- rega pasar lan target rega analis:
Analisis umum perusahaan:NuCana NCNA
Produk sing diprodhuksi NuCana PLC

The use of manufacturing outsourcing in the UK and US stabilizes costs for NuCana plc (NCNA), rendering the issuer's forward P/S ratio a key indicator of market expectations for future revenue. This ratio correlates current market capitalization with projected sales, allowing investors to assess the asset's degree of overvaluation and the risk of capital stagnation should the multiple compress amid a general cooling of demand.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|Cardiff Oncology - Multiplikator Forward P/S|Rega forward marang dodolan BYSI (BeyondSpring Pharma)|BCAB: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep lixte.com (LIXT)|Rasio rega marang prakiraan pendapatan citiuspharma.com|CLRB: Rega forward marang dodolan|Multiplikator Forward P/S BLRX|Multiplikator Forward P/S Can-Fite (CANF)|Rasio rega marang prakiraan pendapatan Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Rega mangsa ngarep marang pendapatan|SLXN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan